Physician profile
Andrew Eugene Bean
NPI 1093202004
$4,521.10
in general payments reported to CMS, 2019-2025
14 companies · $595 in 2025
The $595 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,320 · 2023: $1,802 · 2024: $803 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,301 · Consulting Fee: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,300.67 |
| Consulting Fee | $900.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,871.84 | 2023-2025 | Xen Glaucoma Treatment System, Durysta, Alphagan P |
| Alcon Vision LLC | $1,193.47 | 2022-2025 | Argos, Centurion, Hydrus Microstent |
| Glaukos Corporation | $746.47 | 2022-2023 | |
| Nova Eye, INC. | $175.16 | 2023-2025 | |
| Rxsight INC | $101.10 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Tarsus Pharmaceuticals, INC. | $88.04 | 2025 | Xdemvy |
| Regeneron Healthcare Solutions, INC. | $84.23 | 2022 | |
| Bausch & Lomb Americas INC. | $68.33 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Thea Pharma INC. | $62.95 | 2023-2025 | Iyuzeh |
| New World Medical,INC. | $40.33 | 2022-2024 | Streamline, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Ocular Therapeutix, INC. | $29.15 | 2023 | Dextenza |
| Harrow Eye, LLC | $23.56 | 2024 | Vevye |
| Amgen INC. | $19.11 | 2024 | Tepezza |
| Oyster Point Pharma, INC. | $17.36 | 2023 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Bean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.